Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate With Vertebral Fracture as an Index -

Next Previous
X
Search
Trial Profile

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate With Vertebral Fracture as an Index -

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 19 Jan 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibandronic acid (Primary) ; Risedronic acid
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MOVER
  • Sponsors Chugai Pharmaceutical; Taisho Pharmaceutical

    • Most Recent Events

    • 15 Sep 2014 Subgroup analysis results presented at the 36th Annual Meeting of the American Society for Bone and Mineral Research.
    • 05 Apr 2014 Results presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 06 Oct 2013 Tolerability results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top